Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Aligos Therapeutics (ALGS) EBT Margin (2021 - 2025)

Aligos Therapeutics filings provide 5 years of EBT Margin readings, the most recent being 11746.15% for Q4 2025.

  • On a quarterly basis, EBT Margin fell 925758.0% to 11746.15% in Q4 2025 year-over-year; TTM through Dec 2025 was 1092.36%, a 98345.0% increase, with the full-year FY2025 number at 1092.36%, up 253212.0% from a year prior.
  • EBT Margin hit 11746.15% in Q4 2025 for Aligos Therapeutics, down from 4248.45% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 13868.49% in Q1 2025 to a low of 16368.57% in Q1 2023.
  • Median EBT Margin over the past 5 years was 1776.41% (2021), compared with a mean of 2792.01%.
  • Biggest five-year swings in EBT Margin: tumbled -1498537bps in 2023 and later skyrocketed 1888852bps in 2025.
  • Aligos Therapeutics' EBT Margin stood at 10292.1% in 2021, then skyrocketed by 98bps to 157.02% in 2022, then crashed by -785bps to 1389.85% in 2023, then plummeted by -79bps to 2488.58% in 2024, then plummeted by -372bps to 11746.15% in 2025.
  • The last three reported values for EBT Margin were 11746.15% (Q4 2025), 4248.45% (Q3 2025), and 1624.66% (Q2 2025) per Business Quant data.